Cover Image

Evaluating amyloid-beta as a surrogate endpoint in trials of anti-amyloid drugs in Alzheimer's disease: a Bayesian meta-analysis

Fuente: arXiv

Saved in:

Bibliographic Details
Main Authors:	Ren, Sa, Singh, Janharpreet, Gsteiger, Sandro, Cogley, Christopher, Reed, Ben, Abrams, Keith R, Dawoud, Dalia, Owen, Rhiannon K, Tappenden, Paul, Quinn, Terrence J, Bujkiewicz, Sylwia
Format:	Preprint
Published:	2025
Subjects:	Applications
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Use of surrogate endpoints in health technology assessment: a review of selected NICE technology appraisals in oncology
by: Wheaton, Lorna, et al.
Published: (2024)

Methods of multi-indication meta-analysis for health technology assessment: a simulation study
by: Glynn, David, et al.
Published: (2025)

Meta-analysis and network meta-analysis of time-to-event outcomes with non-proportional hazards: a Bayesian time-varying hazard ratio approach
by: Owen, Rhiannon K, et al.
Published: (2026)

Understanding the impact of amyloid beta targeted therapies on biomarkers and clinical endpoints in Alzheimer's disease
by: Ronald C. Petersen, et al.
Published: (2025)

What are the reasons for the repeated failures of clinical trials with anti-amyloid drugs for AD treatment?
by: Orestes Vicente Forlenza
Published: (2025)

Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease
by: Guoqiao Wang, et al.
Published: (2024)

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab
by: Anwer, Sumayya, et al.
Published: (2025)

A New Frequentist Implementation of the Daniels and Hughes Bivariate Meta‐Analysis Model for Surrogate Endpoint Evaluation
by: Dan Jackson, et al.
Published: (2025)

Associations of cerebral amyloid beta and tau with cognition from midlife
by: Mitzi M. Gonzales, et al.
Published: (2024)

Structural and functional analysis of TREM2 interactions with amyloid beta reveal molecular mechanisms that drive phagocytosis of oligomeric amyloid beta
by: Jessica A Greven, et al.
Published: (2024)

Plasma amyloid beta biomarkers predict amyloid positivity and longitudinal clinical progression in mild cognitive impairment
by: Takuya Ataka, et al.
Published: (2024)

No replicating evidence for anti‐amyloid‐β autoantibodies in cerebral amyloid angiopathy‐related inflammation
by: Emma van den Berg, et al.
Published: (2024)

Host‐dependent variability in amyloid‐beta propagation and deposition
by: Salvatore Saieva, et al.
Published: (2025)

Clinical and MRI features associated with amyloid positivity in secondary screening for anti–amyloid‐β therapy
by: Kazuki Yamada, et al.
Published: (2026)

ASC speck mediated beta‐amyloid seeding in Alzheimer's disease
by: Michael T. Heneka
Published: (2025)

DNA methylation signatures can predict amyloid‐beta burden
by: Michael Vacher
Published: (2024)

Bayesian Profile Regression using Variational Inference to Identify Clusters of Multiple Long-Term Conditions Conditioning on Mortality in Population-Scale Data
by: Rafferty, James, et al.
Published: (2026)

Treatment‐related amyloid clearance (TRAC): a framework to characterize patients in the era of anti‐amyloid therapies
by: Renaud La Joie, et al.
Published: (2025)

Assessing amyloid PET positivity and cognitive function in Down syndrome to guide clinical trials targeting amyloid
by: Sophia Krasny, et al.
Published: (2024)

Genetic moderation on the relationship between brain white matter hyperintensities and amyloid‐beta
by: Yuen Yan Wong, et al.
Published: (2025)

Standardization of criteria in MacCAT‐T and MacCAT‐CR for monoclonal anti–beta‐amyloid antibodies: A Delphi study
by: Jonas Karneboge, et al.
Published: (2025)

Inhibition of soluble TNFa in conjunction with anti‐amyloid immunotherapy
by: Katelynn E. Krick, et al.
Published: (2025)

HSP110 is a modulator of amyloid beta (Aβ) aggregation and proteotoxicity
by: Sabrina Montresor, et al.
Published: (2024)

Noninvasive imaging of amyloid‐beta and tau in rodent and nonhuman primate models
by: Ruiqing Ni, et al.
Published: (2025)

Mapping amyloid beta predictors of entorhinal tau in preclinical Alzheimer's disease
by: Jafar Zamani, et al.
Published: (2025)

Cryo‐EM structures of amyloid beta and tau filaments in down syndrome
by: Anllely Fernandez, et al.
Published: (2024)

White matter hyperintensity modulates the amyloid‐tau‐cognition association and anti‐amyloid treatment efficacy in asymptomatic older adults
by: Zixuan Lin, et al.
Published: (2025)

Learning plug-in surrogate endpoints for randomized experiments
by: Margueritte, Alessandro-Umberto, et al.
Published: (2026)

Mouse models for studying anti‐amyloid antibody‐induced ARIA
by: Cynthia A Lemere
Published: (2025)

Determining eligibility for anti‐amyloid treatments using blood biomarkers
by: Suzanne E. Schindler, et al.
Published: (2025)

Protein disulfide isomerase dissolves and detoxifies oligomeric assemblies of amyloid beta peptide
by: Antonio Mele, et al.
Published: (2026)

In vivo mapping of cortical amyloid beta‐myelin coupling in preclinical Alzheimer's disease
by: Mercedes Atienza, et al.
Published: (2026)

Proteome‐wide analyses identifies plasma immune regulators of amyloid‐beta progression
by: Michael R. Duggan, et al.
Published: (2024)

Age‐ and sex‐effects on tau PET binding in the absence of beta‐amyloid pathology
by: Diana A Hobbs, et al.
Published: (2025)

Circulating amyloid beta 1‐40 peptide as an associate of renal function decline
by: Georgios Mavraganis, et al.
Published: (2025)

Relationship of cognitive decline with glucocerebrosidase activity and amyloid‐beta 42 in DLB and PD
by: Maria Camila Gonzalez, et al.
Published: (2025)

Evidence for impaired clearance leading to amyloid beta (Aβ) accumulation in the Alzheimer’s eye
by: Printha Wijesinghe, et al.
Published: (2024)

Characterizing Japanese older adults without dementia by amyloid PET status: A comparative study of amyloid‐positive and amyloid‐negative groups from Japanese trial‐ready cohort study
by: Saki Nakashima, et al.
Published: (2026)

Modeling amyloid plaque turnover dynamics improves characterization of drug effects
by: Eline van Maanen, et al.
Published: (2025)

Demographic representation in Phase III clinical trials of anti‐amyloid therapy for Alzheimer’s disease: a cross‐sectional analysis
by: Justine Tin Nok Chan, et al.
Published: (2025)